Saturday 17 October 2026
Export AVTX’s income statement to Excel — free account
Avalo Therapeutics, Inc.
AVTX Healthcare Biotechnology
Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024. In the quarter to June 2026, revenue fell 70.1%, EPS grew 56.8% and free cash flow grew 75.7%, each against the same quarter a year earlier.
11.27
0.74
−6.16%
Follow AVTX
Avalo Therapeutics, Inc. (AVTX) P/E ratio
Avalo Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 13.1× (March 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 7.7× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.1× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 29 more quarters | Free account |
Against its own ten years
Low 0.0×
High 13.1×
Ten-year median
0.0×
Current reading's percentile
79
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AVTX Avalo Therapeutics, Inc. | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| GYRE Gyre Therapeutics, Inc. compare | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| SLDB Solid Biosciences Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | n/m |
| PRME Prime Medicine, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)